Oncogenic mutation-driven metabolism-immunity regulatory axis: Potential prospects for thyroid cancer precision therapy
Authors:
Open Access
- 25 September 2025
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1880 (6) , 189459
Abstract
No abstract availableKeywords
Funding Information
- Lanzhou University (Ldyyyn2021\u201030)
- Natural Science Foundation of Gansu Province (17JR5RA272)
- Natural Science Foundation of Gansu Province (22JR5RA923)
This publication has 238 references indexed in Scilit:
- Mechanistic Foundations of KRAS‐Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal MicroenvironmentAdvanced Science, 2025
- Thyroid CancerJAMA, 2024
- Metabolic reprogramming in cancer: Mechanisms and therapeuticsMedcomm, 2023
- Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 studyCancer, 2023
- Signaling, metabolism, and cancer: An important relationship for therapeutic interventionJournal of Cellular Physiology, 2021
- TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti‐CTLA4 treatmentCancer Medicine, 2020
- Enhancing anticancer activity of checkpoint immunotherapy by targeting RASMedcomm, 2020
- Inhibition of IL‐6‐JAK/Stat3 signaling in castration‐resistant prostate cancer cells enhances the NK cell‐mediated cytotoxicity via alteration of PD‐L1/NKG2D ligand levelsMolecular Oncology, 2017
- Statins enhance peroxisome proliferator-activated receptor γ coactivator-1α activity to regulate energy metabolismJournal of Molecular Medicine, 2009
- In vivo evidence of duality effects for lovastatin in a nude mouse cancer modelInternational Journal of Cancer, 2009